Newsfeeds - Spark Newswire

6 minute read

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates

Today, 11:38 PM

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date period to 45. This is just one short of NME approvals received for the same period last year.

ABBV

2 minute read

Earnings

Reata Pharmaceuticals’s Return On Capital Employed Overview

By Benzinga Insights

Today, 11:38 PM

According to Benzinga Pro data, during Q3, Reata Pharmaceuticals (NASDAQ:RETA) posted sales of $7.39 million. Earnings were up 3.38%, but Reata Pharmaceuticals still reported an overall loss of $58.09 million.

RETA

1 minute read

Reata Pharmaceuticals: Q3 Earnings Insights

By Benzinga Insights

Today, 11:38 PM

Reata Pharmaceuticals (NASDAQ:RETA) reported its Q3 earnings results on Monday, November 8, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

RETA

1 minute read

Reata Pharmaceuticals Q3 EPS $(1.27) Up From $(1.31) YoY, Sales $7.40M Up From $1.40M YoY

By Benzinga Newsdesk

Today, 11:38 PM

Reata Pharmaceuticals (NASDAQ:RETA) reported quarterly losses of $(1.27) per share. This is a 3.05 percent increase over losses of $(1.31) per share from the same period last year. The company reported $7.40 million in

RETA

12 minute read

Earnings Scheduled For November 8, 2021

By Benzinga Insights

Today, 11:38 PM

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.

ACAD

1 minute read

Earnings

A Preview Of Reata Pharmaceuticals’s Earnings

By Benzinga Insights

Today, 11:38 PM

Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that Reata Pharmaceuticals will likely report an Earnings Per Share (EPS) of $-2.16

RETA

4 minute read

The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs

By Shanthi Rexaline

Today, 11:38 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

2 minute read

FDA
News

Reata Pharmaceuticals Plans NDA Submission For Omaveloxolone In First Quarter Of 2022 Following Completion Of Pre-NDA Meeting With FDA

By Benzinga Newsdesk

Today, 11:38 PM

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it has completed its pre-New Drug

RETA

2 minute read

Earnings

Reata Pharmaceuticals’s Return on Invested Capital Overview

By Benzinga Insights

Today, 11:38 PM

Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q2 sales of $2.22 million. Earnings fell to a loss of $60.13 million, resulting in a 9.5% decrease from last quarter.

RETA

7 minute read

85 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:38 PM

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.

ABVC